Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Novo Nordisk · Phase 3 · Completed · Enrollment 3731

NCT01272219

EudraCT 2008-001049-24

Y axis: Change in body weight from baseline, %

5004812162024364860Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68), week 56, 0.69%Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), week 56, 2.91%Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)Liraglutide Placebo, no Pre-diabetes, week 56, 0.28%Liraglutide Placebo, no Pre-diabetes

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68): week 56 0.69%
  • Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68): week 56 2.91%
  • Liraglutide Placebo, no Pre-diabetes: week 56 0.28%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.